Every material Form 8-K OMEROS CORP has filed with the SEC since August 12, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On October 28, 2026, Omeros's Compensation Committee granted CEO Gregory A. Demopulos an option to buy up to 500,000 shares, vesting only if stock-price hurdles of $25.00 to $40.00 are met and he remains in service. The committee cited his 2025 achievements, including FDA approval of YARTEMLEA and the sale of zaltenibart to Novo, and said the award was set below peer-level long-term incentives. For shareholders, the award pays out only if the stock rises substantially, but any shares issued on exercise would dilute existing holders.
Option covers up to 500,000 shares of common stock, with an exercise price of $17.88, the October 28, 2026 closing price
Four tranches vest at 30-day volume-weighted average prices of $25.00, $30.00, $35.00 and $40.00, about 40%, 68%, 96% and 124% above the grant-date close
Time condition: 25% of each tranche becomes eligible one year after grant, with the remainder vesting in monthly installments over the following 36 months
Omeros Corporation's board increased its size to nine directors on August 12, 2026, and appointed Joseph Schocken as a director effective immediately. The board also named him to the Audit Committee, and he received a stock option for 30,000 shares under the company's non-employee director pay policy.
Joseph Schocken, 79, appointed director effective August 12, 2026; board expanded to nine directors
Initial term runs until the 2027 annual meeting of shareholders, or earlier resignation or removal
Appointed to the Audit Committee; granted a stock option for 30,000 shares of common stock
Omeros reported second-quarter 2026 net product revenue of $28.5 million for YARTEMLEA, up from $9.9 million in the first quarter, and an operating gain of $0.1 million after a $17.4 million operating loss in the first quarter. GAAP net income fell to $13.2 million, or $0.18 per share, from $56.1 million in the first quarter, which included a larger $73.1 million non-cash gain. The company also completed July repurchases that cut its 2029 Notes principal to about $40.3 million and reduced potential conversion shares.
Net revenue of $28.5 million in Q2 2026 versus $9.9 million in Q1 2026; gross revenue was $32.2 million
Net income of $13.2 million ($0.18 per share) versus $56.1 million in Q1, with non-cash gains of $11.5 million in Q2 and $73.1 million in Q1
Non-GAAP adjusted net income of $1.8 million ($0.02 per share) in Q2 versus an adjusted net loss of $17.1 million in Q1
Cash and short-term investments of $132.0 million at June 30, 2026; 2029 Notes repurchases totaled $60.2 million in July 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OMEROS CORP filing is on SEC EDGAR ↗. 8-K briefs of other companies →